Conference Roundup

Sydnexis reports positive Phase 3 results for low-dose atropine in pediatric myopia

Sydnexis, Inc announced topline results from its Phase 3 STAR trial of SYD-101, a proprietary low-dose atropine formulation, showing significant reductions in myopia progression in children at AMCP Nexus 2025. The STAR (Study of Atropine for the Reduction of Myopia Progression) trial, the largest global pediatric myopia study to date,...